Axsome Therapeutics, Inc.
AXSM
$158.88
$1.010.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 196.00M | 170.99M | 150.04M | 121.46M | 118.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 196.00M | 170.99M | 150.04M | 121.46M | 118.77M |
| Cost of Revenue | 12.33M | 11.91M | 13.45M | 9.79M | 10.51M |
| Gross Profit | 183.67M | 159.08M | 136.59M | 111.67M | 108.25M |
| SG&A Expenses | 169.30M | 150.24M | 130.28M | 120.79M | 113.27M |
| Depreciation & Amortization | 1.61M | 1.61M | 1.59M | 1.57M | 1.61M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 232.02M | 203.92M | 194.86M | 176.93M | 180.40M |
| Operating Income | -36.03M | -32.92M | -44.82M | -55.47M | -61.63M |
| Income Before Tax | -28.13M | -47.23M | -48.93M | -59.41M | -74.83M |
| Income Tax Expenses | 430.00K | -- | -960.00K | -- | 85.00K |
| Earnings from Continuing Operations | -28.56M | -47.23M | -47.97M | -59.41M | -74.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.56M | -47.23M | -47.97M | -59.41M | -74.91M |
| EBIT | -36.03M | -32.92M | -44.82M | -55.47M | -61.63M |
| EBITDA | -34.30M | -31.20M | -43.11M | -53.75M | -59.90M |
| EPS Basic | -0.56 | -0.94 | -0.97 | -1.22 | -1.54 |
| Normalized Basic EPS | -0.46 | -0.43 | -0.59 | -0.74 | -0.82 |
| EPS Diluted | -0.56 | -0.94 | -0.97 | -1.22 | -1.54 |
| Normalized Diluted EPS | -0.46 | -0.43 | -0.59 | -0.74 | -0.82 |
| Average Basic Shares Outstanding | 50.63M | 50.02M | 49.44M | 48.87M | 48.54M |
| Average Diluted Shares Outstanding | 50.63M | 50.02M | 49.44M | 48.87M | 48.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |